Baird Upgrades Mayville Engineering to Outperform, Announces $15 Price Target

Baird analyst Mircea Dobre upgrades Mayville Engineering (NYSE:MEC) from Neutral to Outperform and announces $15 price target.

byBenzinga Newsdesk

November 3, 2022

1 minute read

Baird analyst Mircea Dobre upgrades Mayville Engineering (NYSE:MEC) from Neutral to Outperform and announces $15 price target.

Benchmark Upgrades Incyte After Stock Selloff

By Priya Nigam

July 20, 3:28 PM

The recent downturn in Incyte Corporation’s (NASDAQ: INCY) share price offers an entry opportunity, with the FDA likely to approve ruxolitinib in chronic GVHD indication in September 2021, according to Benchmark.

INCY

Lake Street Downgrades Apollo Endosurgery to Hold, Lowers Price Target to $10

By Benzinga Newsdesk

November 30, 10:16 AM

Lake Street analyst Frank Takkinen downgrades Apollo Endosurgery (NASDAQ:APEN) from Buy to Hold and lowers the price target from $14 to $10.

APEN

Intercept Announces Efficacy And Safety Data From Phase 3 REGENERATE Study In Liver Fibrosis Fue To NASH To Be Presented At NASH-TAG Conference 2023 Jan 6-7

By Benzinga Newsdesk

January 4, 10:08 AM

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

ICPT